Clinical Trial Update: Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase II trial of erlotinib (Tarceva) in advanced bronchioloalveolar cell variant of non-small cell lung cancer completed with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchioloalveolar Cell Variant of Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Bronchioloalveolar Cell Variant of Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-01-20